🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An under appreciated fact in some tumors…it is easier (lower numeric/size threshold) to progress (and trigger PFS event) when you have less disease/smaller tumors (or have had a better response leading to smaller tumors) #ASH24

We have several scenarios in chronic #lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a PFS regulatory driven study. In absence of cure/OS the real question for patients/doctors is AB followed by C at relapse (PFS2) vs ABC (PFS1) all together #ASH24

In watching/making presentations good to keep this important abstract in mind #ASH24

The relevance of this issue is proportional to the single agent activity of C, greater/higher activity makes the single agent option later more relevant #ASH24

Five-year follow-up #ClincialTrial data evaluating the addition of oral azacitidine to the CHOP #chemotherapy regimen for peripheral T-cell #lymphoma was shared at #ASH24 by Dr. Jia Ruan: bit.ly/4gC7X9x

Live from #ASH24: Caitie Gribbin presented on the role of follicular dendritic cells (FDCs) in follicular #Lymphoma bit.ly/4fXGSNY

Dr. Jia Ruan presented phase 2 #ClinicalTrial results at #ASH24 evaluating the effectiveness of two different therapy combinations for patients with mantle cell #Lymphoma (#MCL): bit.ly/4iiXmBS

If showing PFS by response subgroups it is really important to first show the PFS of the full population…..#ASH24

Biomedical innovation goes beyond traditional drug & device development. Hear the unique advantages & challenges clinicians face in developing and commercializing their innovations. 🔗deanssymposium.eventbrite.com WCM Emergency Medicine Weill Cornell Medicine Radiology Weill Cornell Medicine Ob/Gyn Weill Cornell Medicine Psychiatry

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers. news.cornell.edu/stories/2024/1…

Nice leadership lessons: How best to describe the ascending Commanders? As a complete collective. washingtonpost.com/sports/2024/12…

NIH In Your State - United For Medical Research unitedformedicalresearch.org/nih-in-your-st…

Even with indirect costs as they have been previously, grants do not fully cover the costs of research.

Leadership isn’t about wielding power—it’s about understanding people. Empathy fuels connection, and connection fuels action. Want to inspire? Start by listening.

Great collaboration with Erin Mulvey @DrSarahruth The Future of Follicular Lymphoma Management: Strategies on the Horizon | Blood | American Society of Hematology ashpublications.org/blood/article/…

Engage with leading experts in hematology-oncology at Great Debates in Hematologic Malignancies, where cutting-edge advancements and controversial topics in blood cancer care take center stage. Big Questions. Bold Debates. Better Outcomes. ➡️ hmpglobalevents.com/gdhem Jessica Altman, MD

2 days left to apply for the ASCO/AACR Methods in Clinical Trials Workshop!

🩸 Key Debate at Great Debates in Hematologic Malignancies When should BTK inhibitors be used to treat mantle cell lymphoma? Should they be introduced upfront—or reserved for second-line treatment? Join Tycel Phillips, MD (Tycel Phillips) and John Leonard, MD (John P. Leonard, MD)

Great news

Excited to be in Chicago for the Alliance for Clinical Trials in Oncology spring meeting to present on biomarkers in follicular lymphoma. Thanks for the invite John P. Leonard, MD!